Lyra also reported success on key secondary endpoints. These included improvements in broader symptom scores and patient ...

Lyra's LYR-210 met key goals in a Phase 3 trial for chronic rhinosinusitis, showing early and sustained symptom relief with a ...

Researchers have found in a new study that compared to traditional open sinus surgery, nasal endoscopy offers a safer and ...

Rajkot: A 47-year-old factory worker developed a massive nasal polyp, 10 centimetres long, which doctors attribute to his ...

Cepacol® understands the discomfort that nasal congestion and sore throats can bring to your daily life and offers a wide ...

The rally comes after the biotech company announced that its drug candidate, LYR-210, delivered statistically significant ...

As you know, the older we get, the higher our likelihood is of developing certain conditions and diseases. For instance, people in their 30s and 40s may develop nasal polyps, benign (noncancerous) ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

Nasal endoscopic surgery for chronic sinusitis with nasal polyps results in shorter operative time, reduced intraoperative blood loss, and fewer postoperative complications compared to traditional ...

Shares of Lyra Therapeutics, Inc. (LYRA) rocketed 370% on Monday after the company announced positive results from its ...

Sanofi and Regeneron's fast-growing immunology drug Dupixent is on course for a third indication in Europe after being recommended for approval as a treatment for people with nasal polyps.

Lyra Therapeutics (NASDAQ:LYRA) saw its stock soar by 180% after releasing encouraging Phase 3 results for its lead ...